JBC Transcription and Nuclear Factor Monoclonals

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M207050200 on October 21, 2002

J. Biol. Chem., Vol. 277, Issue 52, 50959-50965, December 27, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/52/50959    most recent
M207050200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yan, F.
Right arrow Articles by Polk, D. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yan, F.
Right arrow Articles by Polk, D. B.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Probiotic Bacterium Prevents Cytokine-induced Apoptosis in Intestinal Epithelial Cells*

Fang YanDagger and D. Brent PolkDagger §

From the Departments of Dagger  Pediatrics and § Cell and Developmental Biology, Division of Gastroenterology, Hepatology, and Nutrition, Vanderbilt University School of Medicine, Nashville, Tennessee 37232

Received for publication, July 15, 2002, and in revised form, October 4, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Probiotic bacteria are microorganisms that benefit the host by preventing or ameliorating disease. However, little information is known regarding the scientific rationale for using probiotics as alternative medicine. The purpose of this paper is to investigate the mechanisms of probiotic beneficial effects on intestinal cell homeostasis. We now report that one such probiotic, Lactobacillus rhamnosus GG (LGG), prevents cytokine-induced apoptosis in two different intestinal epithelial cell models. Culture of LGG with either mouse or human colon cells activates the anti-apoptotic Akt/protein kinase B. This model probiotic also inhibits activation of the pro-apoptotic p38/mitogen-activated protein kinase by tumor necrosis factor, interleukin-1alpha , or gamma -interferon. Furthermore, products recovered from LGG culture broth supernatant show concentration-dependent activation of Akt and inhibition of cytokine-induced apoptosis. These observations suggest a novel mechanism of communication between probiotic microorganisms and epithelia that increases survival of intestinal cells normally found in an environment of pro-apoptotic cytokines.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The human gastrointestinal microflora establishes at birth and acquires through a series of colonizations more than 400 bacterial species in the adult (1). Recent evidence clearly demonstrates that commensal bacteria regulate intestinal epithelial development and function (2, 3), and interruption of these interactions results in pathological conditions. Probiotics, as described by Lilly and Stillwell (4), are living microorganisms with low or no pathogenicity that exert beneficial effects on the health of the host. In human clinical trials the non-pathogenic Gram-positive commensal Lactobacilli found in the human and mouse gastrointestinal tracts have been considered as probiotics with beneficial health effects, including enhanced lymphocyte proliferation (5), innate and acquired immunity (6), and anti-inflammatory cytokine production (7). Lactobacillus rhamnosus GG (LGG),1 a bacterium used in the production of yogurt, is one of the best-studied probiotic bacteria in clinical trials. It is effective in preventing and treating diarrhea (8), recurrent Clostridium difficile (9), primary rotavirus infections (10), and atopic dermatitis (11). Therefore, manipulation of enteric microflora by selective living microorganisms termed probiotics are promoted by practitioners of alternative health measures.

There is increasing evidence that probiotic Lactobacillus species play a role in the treatment of inflammatory bowel disease (IBD). In this disease, abnormal immune responses cause inflammation that appears to be stimulated by elements of the enteric microenviroment, including normal and pathogenic organisms (12). Reduction of Lactobacillus and Bifidobacteria has been found in colonic biopsies of patients with IBD (13, 14). Although conventional therapeutic strategies focus on suppression or modulation of host immunity, modification of enteric microflora by probiotics may have a role in treating IBD. Several Lactobacillus strains prevent or attenuate intestinal inflammation in the interleukin (IL)-10-/- mouse model, which spontaneously develops enterocolitis (15, 16). LGG increases anti-inflammatory IL-10 levels in children (7). Furthermore, LGG has been suggested as adjunctive therapy for Crohn's disease (17).

Putative mechanisms of the action of probiotics include regulation of cytokine production (18), such as stimulation of mononuclear cells to generate both pro- and anti-inflammatory cytokines (19, 20), enhancement of secretory IgA secretion (21), production of antibacterial substances (22, 23), an increase in the integrity of the intestinal barrier (24), and competition with pathogenic microorganisms for enterocyte binding (25). Yet almost nothing is known regarding the basic molecular mechanisms of probiotic regulation of intestinal epithelial health.

Two common features of IBD involve increased cytokine production (26, 27) and increased apoptosis of intestinal cells (28). We have reported that a central cytokine in the pathogenesis of IBD, tumor necrosis factor (TNF) (27), regulates both anti- and pro-apoptotic signaling pathways, and the balance between these two kinds of signals determines the cell fate (29). Therefore, the purpose of the present study is to investigate the effects of LGG on cytokine-regulated signaling pathways determining intestinal cell fate.

We now report that LGG prevents cytokine-induced apoptosis in mouse or human intestinal epithelial cells. Culture of LGG with colon cells activates the anti-apoptotic Akt/protein kinase B. Further, this model probiotic inhibits activation of the pro-apoptotic p38/mitogen-activated protein (MAP) kinase by TNF, IL-1alpha , or gamma -interferon (IFN). Therefore, LGG promotes intestinal epithelial cell survival through regulation of both anti- and pro-apoptotic signal transduction pathways. These novel observations provide insight into the rationale for LGG as a potential treatment for IBD.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Bacterial Culture and Supernatant Preparation-- LGG (American Type Culture Collection 53103) was incubated in Lactobacillus MRS broth at 37 °C for 24 h, then diluted in MRS broth, and incubated at 37 °C to reach log phase with the density determined as 0.5 at A600 (20). LGG was precipitated from MRS broth (1000 × g, 15 min) and washed twice with phosphate-buffered saline. Heat-killed (hk) LGG was prepared by boiling LGG in phosphate-buffered saline for 1 h and then washing it with phosphate-buffered saline. Lactobacillus acidophilus (American Type Culture Collection 393) and Lactobacillus casei (American Type Culture Collection 4356) were cultured per ATCC guidelines. 107 colony-forming units/ml LGG, L. casei, or L. acidophilus in RPMI cell culture medium were used to treat cells. Salmonella pullorum (provided by Andrew Neish, Emory University, Atlanta, GA) was prepared and incubated with cells as described (30).

Supernatant recovered from LGG culture broth (LGG-s) was generated by centrifuging (1000 × g, 15 min) and filtering (0.2 µm) LGG culture in MRS broth; then the filtrate was concentrated using Centricon Plus-20 (5-100 kDa, Millipore, Bedford, MA) by centrifugation (4000 × g, 1 h) following guidelines from the manufacturer. Protein concentrations were determined by DC protein assay (Bio-Rad) using MRS broth as the control. LGG-conditioned cell culture medium (LGG-cm) was generated by incubating washed LGG (107 colony-forming units/ml) in RPMI cell culture medium at 37 °C for 2 h; the medium was centrifuged twice (1000 × g, 15 min) and then filtered (0.2 µm).

Cell Culture-- Young adult mouse colon (YAMC) cells were grown in RPMI with 5% fetal bovine serum on collagen-coated culture dishes as described previously (31). Clonal cell lines stably expressing pFLAG-cDNA3-kinase-inactive (ki) kinase suppressor of Ras (KSR) or pFLAG-cDNA3-wild-type KSR (provided by Richard Kolesnick, Memorial Sloan-Kettering Cancer Center, New York, NY) were generated as described (32). The kiKSR plasmid expresses a kinase-inactive dominant-negative KSR as previously described (32, 33). Clonal cells were cultured in the presence of G418 (100 µg/ml) until 24 h prior to the experiments. The human colonic epithelial carcinoma cell line, HT 29 cells, was grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. All cells were serum-starved (0.5%) at 37 °C for 24 h before experiments.

Preparation of Cellular Lysates-- Lysates were prepared from cells treated with murine TNF, IL-1alpha , or gamma -IFN (Pepro Tech, Inc., Rocky Hill, NJ) for the indicated times in the presence or absence of LGG, LGG-s, LGG-cm, hk-LGG, phosphoinositide (PI) 3-kinase inhibitors, wortmannin (Sigma) or LY294002 or p38 inhibitors (Biomol, Plymouth Meeting, PA) SB203580 or SB202190. Cell monolayers were washed twice with ice-cold phosphate-buffered saline and then scraped into cell lysis buffer (20 mM HEPES (pH 7.5), 1 mM orthovandate, 50 mM beta -glycerophosphate, 10 mM sodium pyrophosphate with leupeptin (10 µg/ml), aprotinin (10 µg/ml), phenylmethylsulfonyl fluoride (18 µg/ml), and 1% Triton X-100). The scraped suspensions were centrifuged (14,000 × g, 10 min) at 4 °C, and protein content was determined using DC protein assay (Bio-Rad). Equal amounts of cellular lysate protein were mixed with Laemmli sample buffer and separated by SDS-PAGE for Western blot analysis with anti-phospho-Akt, anti-Akt, anti-phospho-p38, anti-p38, anti-Ikappa Balpha , anti-phospho stress-activated protein kinase/c-Jun amino-terminal kinase (SAPK/JNK), anti-SAPK/JNK (Cell Signaling Technology, Beverly, MA), or anti-phospho extracellular signal-regulated kinase (ERK)1/ERK2/MAP kinase (Promega, Madison, WI) antibodies.

Apoptosis Assay-- YAMC and clonal cell lines were cultured on collagen-coated or HT29 cells on non-coated chamber glass slides and were prepared as described above. Following treatment, apoptotic cells were labeled by ApopTag in situ apoptosis detection kits (Intergen, Purchase, NY) using terminal deoxynucleotidyltransferase for detection of positive cells following guidelines from the manufacturer. Apoptotic cells were labeled by fluorescein isothiocyanate-conjugated anti-digoxigenin or anti-digoxigenin peroxidase conjugate and 3,3'-diaminobenzidine as substrate and were then dehydrated and mounted using Vectashield mounting medium. Slides were counterstained with 4,6-diamidino-2-phenylindole (DAPI) by using 1 µg/ml DAPI in mounting medium. The cells were observed by fluorescence microscopy or differential interference contrast. Apoptotic terminal deoxynucleotidyltransferase-mediated dUTP nick-end-labeling (TUNEL) positive cells were determined by counting at least 200 cells in randomly chosen fields and expressing them as a percentage of the total number of cells counted.

Caspase activity was detected in living cells using the sulforhodamine multi-caspase activity kit (Biomol) following guidelines from the manufacturer. Active caspase enzyme in living cells was labeled with cell-permeable sulforhodamine-conjugated valylalanylaspartic acid fluoromethyl ketone, an inhibitor of caspase activity that binds to active caspase enzyme. Cells with increased caspase activity were detected by fluorescence microscopy.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

LGG Prevents Cytokine-induced Apoptosis in Intestinal Epithelial Cells-- Pathological concentrations of TNF inhibit intestinal cell proliferation without inducing apoptosis in YAMC cells (29, 31). Because dominant-negative kiKSR expression induces apoptosis in TNF-treated intestinal cells (29), we used kiKSR-expressing colon cells to test our hypothesis that probiotics prevent TNF-induced apoptosis through regulation of signal transduction pathways. We found that TNF-stimulated apoptosis detected by TUNEL staining in kiKSR-expressing YAMC cells was inhibited by co-culture with viable LGG but was not hkLGG (Fig. 1, A and B). Furthermore, in a model of human intestinal cell apoptosis the effect of a "cytokine mixture" combination of TNF, IL-1alpha , and gamma -IFN is reversed by LGG (Fig. 1D). DAPI staining shows nuclear condensation of the TUNEL-positive intestinal cells undergoing apoptosis (Fig. 1A). To further demonstrate that the observed LGG effect is caused by the inhibition of apoptosis, we used a multi-caspase activity assay in living cells. The increased caspase activity of cells undergoing apoptosis is blocked by viable LGG (Fig. 1C). Interestingly, cell survival is also enhanced by LGG-s, and this inhibitory effect on apoptosis is concentration-dependent (Fig. 1, A-D).


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 1.   LGG inhibits cytokine-induced apoptosis in intestinal epithelial cells. kiKSR-expressing YAMC cells (A-C) or human colonic epithelial carcinoma cell line (HT29) cells (D) were treated with TNF (100 ng/ml) or the "cytokine mixture" combination of TNF (100 ng/ml), IL-1alpha (10 ng/ml), and gamma -IFN (100 ng/ml), respectively, for 6 h in the presence or absence of a 1-h pretreatment with viable LGG, hk-LGG, or concentrated supernatant recovered from LGG culture MRS broth (LGG-s) at the concentrations indicated. Then, cells were fixed for terminal deoxynucleotidyltransferase TUNEL with apoptotic nuclei labeled with fluorescein isothiocyanate and DAPI staining (A and D). Fluorescein isothiocyanate- and DAPI-labeled images were taken from the same field. The percentage of cells undergoing apoptosis from a representative experiment is shown in B. Caspase activity in living cells was detected using a multi-caspase activity assay kit (C). Arrows indicate representative apoptotic nuclei. All experiments in this and subsequent figures were performed on at least three separate occasions.

LGG Regulates Signaling Pathways That Determine Cell Fate-- The balance between anti-apoptotic and pro-apoptotic signal transduction pathways regulates the fate of cells exposed to various stimuli including TNF. Therefore, we studied the effects of LGG on signal transduction pathways that regulate cell fate. LGG or LGG-cm, but not heat-killed LGG, stimulates anti-apoptotic Akt activation determined by antibody against Ser(P)-473-Akt (Fig. 2A). Akt activation is also enhanced by LGG-s in a concentration-dependent manner (Fig. 2, B and C). This activation by either LGG or TNF is blocked by the PI 3-kinase inhibitors, LY294002 or wortmannin, but not by the MEK1 inhibitor, PD98059 (Fig. 2D). Whereas kiKSR expression inhibits TNF activation of Akt, both LGG and LGG-cm stimulate Akt phosphorylation in these cells (Fig. 2E), indicating that TNF and LGG utilize different mechanisms to activate PI 3-kinase upstream of Akt. Nuclear factor (NF) kappa B and ERK/MAP kinase activation are important TNF-activated antiapoptotic signal transduction pathways in intestinal cells (29). TNF stimulates both degradation of the inhibitor of kappa B and activation of ERK1/ERK2. However, LGG does not effect activation of either of these anti-apoptotic molecules (Fig. 2F), which indicates that LGG inhibition of TNF-induced apoptosis is not caused by the disruption of TNF receptor binding activities.


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 2.   LGG or factors recovered in LGG-cm or LGG-s stimulate Akt activation. YAMC (A, B, D, F), HT29 (C), and kiKSR-expressing cells (E) were treated with viable LGG, hk-LGG, LGG-cm, or LGG-s as indicated for 1 h followed by TNF (100 ng/ml, 15 min) treatment. PI 3-kinase inhibitors, wortmannin (100 nM) or LY294002 (10 µM), or MEK1 inhibitor PD98059 (10 µM) was used to pre-treat cells for 1 h before TNF or LGG treatment (D). Akt activation was detected by Western blot analysis of cellular lysates with anti-Ser(P)-473-Akt and anti-Akt antibodies. YAMC cells were treated with LGG for the indicated times, and Ikappa Balpha degradation and ERK1/2 activation were detected by Western blot analysis of cellular lysates with anti-Ikappa Balpha or anti-phospho (P) ERK1/2 antibodies (F).

By using an antibody to phospho-p38 we determined that viable LGG inhibits TNF-induced activation of this pro-apoptotic MAP kinase (Fig. 3, A-C). Unlike Akt activation, inhibition of p38 is not reproduced by factors present in LGG-cm (Fig. 3, A and B). The cytokine-activated pro-apoptotic SAPK/JNK activities are not affected by LGG (Fig. 3D). Collectively these data indicate that LGG promotes survival of intestinal epithelial cells exposed to inflammatory cytokines through activation of specific anti-apoptotic and inhibition of pro-apoptotic signals.


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 3.   LGG blocks cytokine-induced p38 phosphorylation. YAMC (A, D), kiKSR (B), or HT29 (C) cells were treated with TNF (100 ng/ml), IL-1alpha (10 ng/ml), or gamma -IFN (100 ng/ml) as indicated in the presence or absence of a 1-h pretreatment with viable LGG, hk-LGG, or LGG-cm. Cellular lysates were prepared for Western blot analysis with anti-Thr(P)-p38, anti-p38, anti-phospho-SAPK/JNK, and anti-SAPK/JNK antibodies.

Probiotic Bacterium Regulation of Cell Survival Is Strain-specific-- These findings raise an important question. Is this anti-apoptotic response unique to LGG, or is it common to other probiotic commensal or non-pathogenic intestinal microflora? To address this question we studied the effects of two other Gram-positive strains of Lactobacillus, L. acidophilus and L. casei, known to enhance lymphocyte proliferation and immunity (5, 6) or macrophage activation (34), respectively. Whereas these two bacteria stimulate Akt activation, they show no inhibition of TNF-stimulated p38 (Fig. 4A). Accordingly, their inhibitory effect on TNF-induced apoptosis is significantly reduced compared with LGG (Fig. 4B). Furthermore, we studied two Gram-negative bacteria derived from colon flora isolates, Salmonella typhimurium PhoPc and S. pullorum, that have been shown to regulate TNF-stimulated signal transduction pathways in intestinal cells (30). Neither of these attenuate TNF-induced apoptosis in colon cells (Fig. 4, C and D). Therefore, reversal of cytokine-induced apoptosis by LGG does not extend to all commensal or non-pathogenic intestinal microflora. This evidence suggests that a need for caution in selecting "probiotics" for clinical study is warranted and may explain variability in results of clinical trials investigating different probiotics.


View larger version (46K):
[in this window]
[in a new window]
 
Fig. 4.   Regulation of signal transduction and apoptosis in intestinal cells by commensal or non-pathogenic bacteria. YAMC cells were treated with LGG, L. casei (LC), or L. acidophilus (LA) for 1 h followed by 15 min of TNF (100 ng/ml) treatment as indicated in A. Akt and p38 activation was detected as before. LC, LA (B), or S. pullorum (C and D), which were prepared as indicated under "Experimental Procedures," were incubated with kiKSR-expressing cells for 1 h prior to the addition of TNF (100 ng/ml) and then treated for 6 h. The cells were prepared for TUNEL staining as before (C). The percentage of cells undergoing apoptosis in a representative experiment is shown (B and D).

Akt and p38 MAP Kinase Determine the Fate of Intestinal Epithelial Cells Exposed to TNF-- To determine the relative importance of Akt activation and inhibition of p38 activity in regulating the fate of intestinal cells exposed to TNF, we used pharmacological inhibitors. A blockade of Akt activation by PI 3-kinase inhibitors (as shown in Fig. 2D) increases apoptosis in YAMC cells treated with TNF (Fig. 5, A and B), whereas inhibitors of p38 block apoptosis in TNF-treated kiKSR-expressing cells (Fig. 5, C and D). As expected, both p38 inhibitors reduce p38 activation at concentrations that were studied (Fig. 5E). These results are consistent with the hypothesis that activation of Akt and inhibition of p38 by LGG are central to its anti-apoptotic effect.


View larger version (55K):
[in this window]
[in a new window]
 
Fig. 5.   Akt functions as an inhibitor of apoptosis, whereas p38 promotes apoptosis in cells exposed to TNF. YAMC cells (A and B) or kiKSR-expressing YAMC cells (C-E) were treated with TNF for 6 h in the absence or presence of 1-h pretreatment with wortmannin (100 nM), LY294002 (10 µM), SB203580 (10 µM), or SB202190 (10 µM) as indicated. TUNEL staining was used to identify apoptotic nuclei by peroxidase. The cells were visualized by differential interference contrast microscopy (A and C). The percentage of cells undergoing apoptosis from representative experiments is shown (B and D). p38 phosphorylation was detected as described in Fig. 3.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The lumen of the gastrointestinal tract has evolved with a complex ecosystem that includes commensal and pathogenic bacteria with the capability of cross-species communication (3, 35). Lilly and Stillwell (4) described microbes that had potential benefit to their hosts as probiotics. We have studied the relationships between Lactobacillus GG, as a model probiotic, and the intestinal epithelial cell, the point of first contact with the host. Our novel findings demonstrate that LGG promotes the survival of intestinal epithelial cells through the activation of the anti-apoptotic Akt/protein kinase B and inhibition of the pro-apoptotic p38 MAP kinase. LGG produces a factor that activates Akt independent of bacterial cellular interaction.

It is possible that other commensal organisms with potential probiotic activity (6, 30, 36, 37) could prevent cytokine-induced apoptosis. Although some of those we tested reduced apoptosis, none were as effective as LGG, and LGG appeared unique in its ability to block p38 MAP kinase activation. These findings extend our understanding of the complexity of the host commensal relationship and suggest that intestinal cell survival in its cytokine-rich environment may be regulated by the presence of beneficial microbes. This effect appears to require live bacteria, because either heat treatment (Figs. 2 and 3) or glutaraldehyde fixation (data not shown) prevents LGG regulation of Akt or p38 MAP kinase.

The mechanisms by which intestinal bacteria modulate the inflammatory process are complex and incompletely understood. Probiotic bacteria interact with three components of the gastrointestinal tract including intestinal epithelial cells, luminal flora, and the mucosal immune cells. It is known that probiotic bacteria can regulate lymphocyte cytokine production (18-20). Nonpathogenic Salmonella species can regulate the immune response by blocking NFkappa B activation and IL-8 production (30). However, these Salmonella species do not alter apoptotic response to cytokine (Fig. 4, B and C), nor does LGG inhibit NFkappa B activation (data not shown). We did not detect NFkappa B activation by either inhibitor of kappa B degradation (Fig. 2F) or NFkappa B p65 subunit nuclear translocation up to 6 h after LGG treatment (data not shown). Although we did not specifically study IL-8 secretion in our cells, it is increased in CaCo2 cells treated with Lactobacillus (38). A commensal Bifidobacterium strain regulates intestinal cell gene expression (3) and promotes its own survival within the host (2). Clearly, the mechanisms of activating intestinal cell signal transduction pathways by commensal bacteria are relevant to the maintenance of this important physical and functional mucosal barrier.

Our current understanding of cell survival suggests that the balance between pro-apoptotic and anti-apoptotic signals generated by cytokines regulates apoptosis (39). Anti-apoptotic signaling pathways initiated by TNF, other cytokines, and growth factors include NFkappa B (40), extracellular ERK1/ERK2/MAP kinase (41), and PI 3-kinase/Akt (42). By contrast, other members of the MAP kinase family, including SAPK/JNK and p38 function as pro-apoptotic signals for a number of cell types (41). KSR is an essential kinase in TNF signal transduction, determining intestinal epithelial cell fate by regulating the anti-apoptotic NFkappa B, ERK/MAP kinase, and Akt pathways (29). However, neither TNF activation of p38 MAP kinase nor SAPK/JNK is inhibited by disruption of KSR signaling. Despite blocking all the anti-apoptotic signals mediated through KSR, LGG still promotes intestinal cell survival (Fig. 1). This effect appears to require blocking p38 MAP kinase activation (Fig. 5B), because Akt activation by the LGG supernatant is insufficient to fully reverse apoptosis (Fig. 1B).

Surprisingly, factors recovered from bacterial culture or conditioned cell culture media reduce apoptosis and activate Akt. Production of these factors does not require bacterial-intestinal cell contact. Previously studies have reported that some Lactobacillus strains produce proteinaceous (23) or protease-insensitive (22) anti-bacterial compounds. However, we are unaware of reports indicating that bacterially produced factors regulate either Akt signal transduction or cell survival pathways. Thus far we have identified two proteins in LGG culture broth with molecular sizes of ~80 and 42 kDa based on SDS-PAGE. These two factors are heat- and protease-sensitive, and their activities are recoverable by electroelution from polyacrylamide gels (data not shown). Clearly, recovery and further characterization of these factors is a high priority.

Our evaluation of LGG as a model probiotic organism reveals an important and novel relationship between intestinal epithelial cell survival and selective microflora. Clearly, this single epithelial layer lining the intestine exists in a relatively hostile environment of pathogenic organisms, toxic waste by-products, and cytokines. This report adds to our understanding of the signal transduction pathways in the intestinal epithelial cell that are regulated by probiotics and commensal organisms to include intestinal cell survival in addition to intestinal homeostasis (3, 30). Therefore, further studies of the molecular basis for probiotic regulation of intestinal epithelium are relevant to understanding normal development as well as the pathogenesis of inflammatory bowel disease.

    ACKNOWLEDGEMENTS

We thank Andrew Neish (Emory University) for S. pullorum and S. typhimurium PhoPc; Valio Ltd. (Helsinki, Finland) for LGG; Sam Wells, Han Liang, Wei Tong, Guinn Wilson, and Mark Frey for excellent technical assistance; the Vanderbilt University Medical Center Imaging Core Research Laboratory (CA68485); and Graham Carpenter, Steve Hanks, and Raymond DuBois for helpful discussions and critical review of the manuscript.

    FOOTNOTES

* This work was supported by a Children's Digestive Health and Nutrition Foundation/Nestle Nutrition Grant (to F. Y.), National Institutes of Health Grants DK10105 (to F. Y.) and DK56008 (to D. B. P.), and the Vanderbilt University Digestive Disease Research Center (DK58404).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Pediatric Gastroenterology, Hepatology, and Nutrition, S4322 MCN, 21st and Garland Ave., Nashville, TN 37232-2576. Tel.: 615-322-7449; Fax: 615-343-8915; E-mail: d-brent.polk@vanderbilt.edu.

Published, JBC Papers in Press, October 21, 2002, DOI 10.1074/jbc.M207050200

    ABBREVIATIONS

The abbreviations used are: LGG, Lactobacillus rhamnosus GG; ERK, extracellular signal-regulated kinase; IBD, inflammatory bowel disease; IFN, interferon; IL, interleukin; ki, kinase-inactive; KSR, kinase suppressor of Ras; LGG-cm, LGG conditioned medium; LGG-s, supernatant recovered from LGG culture broth; MAP, mitogen activated protein; NFkappa B, nuclear factor kappa B; PI, phosphoinositide; SAPK/JNK, stress-activated protein kinase/c-Jun amino-terminal kinase; TNF, tumor necrosis factor; YAMC, young adult mouse colon; hk, heat killed; DAPI, 4,6-diamidino-2-phenylindole; TUNEL, terminal deoxynucleotidyltransferase-mediated dUTP nick-end labeling.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Berg, R. D. (1996) Trends Microbiol. 4, 430-435[CrossRef][Medline] [Order article via Infotrieve]
2. Bry, L., Falk, P. G., Midtvedt, T., and Gordon, J. I. (1996) Science 273, 1380-1383[Abstract]
3. Hooper, L. V., Wong, M. H., Thelin, A., Hansson, L., Falk, P. G., and Gordon, J. I. (2001) Science 291, 881-884[Abstract/Free Full Text]
4. Lilly, D. M., and Stillwell, R. H. (1965) Science 147, 747-748[Abstract/Free Full Text]
5. Kirjavainen, P. V., El-, Nezami, H. S., Salminen, S. J., Ahokas, J. T., and Wright, P. F. (1999) FEMS Immunol. Med. Microbiol. 26, 131-135[CrossRef][Medline] [Order article via Infotrieve]
6. Gill, H. S., Rutherfurd, K. J., Prasad, J., and Gopal, P. K. (2000) Br. J. Nutr. 83, 167-176[CrossRef][Medline] [Order article via Infotrieve]
7. Pessi, T., Sutas, Y., Hurme, M., and Isolauri, E. (2000) Clin. Exp. Allergy 30, 1804-1808[CrossRef][Medline] [Order article via Infotrieve]
8. Marteau, P. R., de Vrese, M., Cellier, C. J., and Schrezenmeir, J. (2001) Am. J. Clin. Nutr. 73, 430S-436S[Abstract/Free Full Text]
9. Gorbach, S. L., Chang, T. W., and Goldin, B. (1987) Lancet 2, 1519[Medline] [Order article via Infotrieve]
10. Szajewska, H., Kotowska, M., Mrukowicz, J. Z., Armanska, M., and Mikolajczyk, W. (2001) J. Pediatr. 138, 361-365[CrossRef][Medline] [Order article via Infotrieve]
11. Kalliomaki, M., Salminen, S., Arvilommi, H., Kero, P., Koskinen, P., and Isolauri, E. (2001) Lancet 357, 1076-1079[CrossRef][Medline] [Order article via Infotrieve]
12. Shanahan, F. (2000) Science 289, 1311-1312[Free Full Text]
13. Fabia, R., Ar'Rajab, A., Johansson, M. L., Andersson, R., Willen, R., Jeppsson, B., Molin, G., and Bengmark, S. (1993) Digestion 54, 248-255[Medline] [Order article via Infotrieve]
14. Favier, C., Neut, C., Mizon, C., Cortot, A., Colombel, J. F., and Mizon, J. (1997) Dig. Dis. Sci. 42, 817-822[CrossRef][Medline] [Order article via Infotrieve]
15. Madsen, K. L., Doyle, J. S., Jewell, L. D., Tavernini, M. M., and Fedorak, R. N. (1999) Gastroenterology 116, 1107-1114[CrossRef][Medline] [Order article via Infotrieve]
16. Schultz, M., Veltkamp, C., Dieleman, L. A., Grenther, W. B., Wyrick, P. B., Tonkonogy, S. L., and Sartor, R. B. (2002) Inflamm. Bowel Dis. 8, 71-80[CrossRef][Medline] [Order article via Infotrieve]
17. Malin, M., Suomalainen, H., Saxelin, M., and Isolauri, E. (1996) Ann. Nutr. Metab. 40, 137-145[Medline] [Order article via Infotrieve]
18. Maassen, C. B., van Holten-Neelen, C., Balk, F., den Bak-Glashouwer, M. J., Leer, R. J., Laman, J. D., Boersma, W. J., and Claassen, E. (2000) Vaccine 18, 2613-2623[CrossRef][Medline] [Order article via Infotrieve]
19. Miettinen, M., Matikainen, S., Vuopio-Varkila, J., Pirhonen, J., Varkila, K., Kurimoto, M., and Julkunen, I. (1998) Infect. Immun. 66, 6058-6062[Abstract/Free Full Text]
20. Miettinen, M., Vuopio-Varkila, J., and Varkila, K. (1996) Infect. Immun. 64, 5403-5405[Abstract]
21. Rodrigues, A. C., Cara, D. C., Fretez, S. H., Cunha, F. Q., Vieira, E. C., Nicoli, J. R., and Vieira, L. Q. (2000) J. Appl. Microbiol. 89, 404-414[CrossRef][Medline] [Order article via Infotrieve]
22. Zamfir, M., Callewaert, R., Cornea, P. C., Savu, L., Vatafu, I., and De Vuyst, L. (1999) J. Appl. Microbiol. 87, 923-931[CrossRef][Medline] [Order article via Infotrieve]
23. Bernet-Camard, M. F., Lievin, V., Brassart, D., Neeser, J. R., Servin, A. L., and Hudault, S. (1997) Appl. Environ. Microbiol. 63, 2747-2753[Abstract]
24. Gotteland, M., Cruchet, S., and Verbeke, S. (2001) Aliment Pharmacol. Ther. 15, 11-17[CrossRef][Medline] [Order article via Infotrieve]
25. Bernet, M. F., Brassart, D., Neeser, J. R., and Servin, A. L. (1994) Gut 35, 483-489[Abstract/Free Full Text]
26. Breese, E. J., Michie, C. A., Nicholls, S. W., Murch, S. H., Williams, C. B., Domizio, P., Walker-Smith, J. A., and MacDonald, T. T. (1994) Gastroenterology 106, 1455-1466[Medline] [Order article via Infotrieve]
27. Sartor, R. B. (1995) Gastroenterol. Clin. N. Am. 24, 475-507[Medline] [Order article via Infotrieve]
28. Iwamoto, M., Koji, T., Makiyama, K., Kobayashi, N., and Nakane, P. K. (1996) J. Pathol. 180, 152-159[CrossRef][Medline] [Order article via Infotrieve]
29. Yan, F., John, S. K., and Polk, D. B. (2001) Cancer Res. 61, 8668-8675[Abstract/Free Full Text]
30. Neish, A. S., Gewirtz, A. T., Zeng, H., Young, A. N., Hobert, M. E., Karmali, V., Rao, A. S., and Madara, J. L. (2000) Science 289, 1560-1563[Abstract/Free Full Text]
31. Kaiser, G. C., and Polk, D. B. (1997) Gastroenterology 112, 1231-1240[CrossRef][Medline] [Order article via Infotrieve]
32. Yan, F., and Polk, D. B. (2001) Cancer Res. 61, 963-969[Abstract/Free Full Text]
33. Zhang, Y., Yao, B., Delikat, S., Bayuomy, S., Lin, X., Basu, S., McGinley, M., Chan-Hui, P., Lichenstein, H., and Kolesnick, R. (1997) Cell 89, 63-72[CrossRef][Medline] [Order article via Infotrieve]
34. Perdigon, G., de Macias, M. E., Alvarez, S., Oliver, G., and de Ruiz Holgado, A. A. (1986) Infect. Immun. 53, 404-410[Abstract/Free Full Text]
35. Tieng, V., Le, Bouguenec, C., du Merle, L., Bertheau, P., Desreumaux, P., Janin, A., Charron, D., and Toubert, A. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 2977-2982[Abstract/Free Full Text]
36. Kirjavainen, P. V., ElNezami, H. S., Salminen, S. J., Ahokas, J. T., and Wright, P. F. A. (1999) Clin. Diagn. Lab Immunol. 6, 799-802[Abstract/Free Full Text]
37. Peranen, J., Auvinen, P., Vitra, H., Wepf, R., and Simons, K. (1996) J. Cell Biol. 135, 153-167[Abstract/Free Full Text]
38. Haller, D., Bode, C., Hammes, W. P., Pfeifer, A. M., Schiffrin, E. J., and Blum, S. (2000) Gut 47, 79-87[Abstract/Free Full Text]
39. Budd, R. C. (2002) J. Clin. Invest. 109, 437-441[CrossRef][Medline] [Order article via Infotrieve]
40. Van Antwerp, D. J., Martin, S. J., Kafri, T., Green, D. R., and Verma, I. M. (1996) Science 274, 787-789[Abstract/Free Full Text]
41. Xia, Z., Dickens, M., Rainegeaud, J., Davis, R. J., and Greenberg, M. E. (1995) Science 270, 1326-1331[Abstract/Free Full Text]
42. Dudek, H., Datta, S. R., Franke, T. F., Birnbaum, M. J., Yao, R., Cooper, G. M., Segal, R. A., Kaplan, D. R., and Greenberg, M. E. (1997) Science 275, 661-665[Abstract/Free Full Text]


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Int ImmunolHome page
C. Guzy, D. Paclik, A. Schirbel, U. Sonnenborn, B. Wiedenmann, and A. Sturm
The probiotic Escherichia coli strain Nissle 1917 induces {gamma}{delta} T cell apoptosis via caspase- and FasL-dependent pathways
Int. Immunol., July 1, 2008; 20(7): 829 - 840.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
A. Borthakur, R. K. Gill, S. Tyagi, A. Koutsouris, W. A. Alrefai, G. A. Hecht, K. Ramaswamy, and P. K. Dudeja
The Probiotic Lactobacillus acidophilus Stimulates Chloride/Hydroxyl Exchange Activity in Human Intestinal Epithelial Cells
J. Nutr., July 1, 2008; 138(7): 1355 - 1359.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
A. Seth, F. Yan, D. B. Polk, and R. K. Rao
Probiotics ameliorate the hydrogen peroxide-induced epithelial barrier disruption by a PKC- and MAP kinase-dependent mechanism
Am J Physiol Gastrointest Liver Physiol, April 1, 2008; 294(4): G1060 - G1069.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. Flanagan, Z. Modrusan, J. Cornelius, A. Chavali, I. Kasman, L. Komuves, L. Mo, and L. Diehl
Intestinal Epithelial Cell Up-Regulation of LY6 Molecules during Colitis Results in Enhanced Chemokine Secretion
J. Immunol., March 15, 2008; 180(6): 3874 - 3881.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
N. Reilly, V. Poylin, M. Menconi, A. Onderdonk, S. Bengmark, and P.-O. Hasselgren
Probiotics potentiate IL-6 production in IL-1beta-treated Caco-2 cells through a heat shock-dependent mechanism
Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2007; 293(3): R1169 - R1179.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
B. Corthesy, H. R. Gaskins, and A. Mercenier
Cross-Talk between Probiotic Bacteria and the Host Immune System
J. Nutr., March 1, 2007; 137(3): 781S - 790S.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
X. Chen, E. G. Kokkotou, N. Mustafa, K. R. Bhaskar, S. Sougioultzis, M. O'Brien, C. Pothoulakis, and C. P. Kelly
Saccharomyces boulardii Inhibits ERK1/2 Mitogen-activated Protein Kinase Activation Both in Vitro and in Vivo and Protects against Clostridium difficile Toxin A-induced Enteritis
J. Biol. Chem., August 25, 2006; 281(34): 24449 - 24454.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
A. Grabig, D. Paclik, C. Guzy, A. Dankof, D. C. Baumgart, J. Erckenbrecht, B. Raupach, U. Sonnenborn, J. Eckert, R. R. Schumann, et al.
Escherichia coli Strain Nissle 1917 Ameliorates Experimental Colitis via Toll-Like Receptor 2- and Toll-Like Receptor 4-Dependent Pathways
Infect. Immun., July 1, 2006; 74(7): 4075 - 4082.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
J. B. Ewaschuk, J. W. Walker, H. Diaz, and K. L. Madsen
Bioproduction of Conjugated Linoleic Acid by Probiotic Bacteria Occurs In Vitro and In Vivo in Mice
J. Nutr., June 1, 2006; 136(6): 1483 - 1487.
[Abstract] [Full Text] [PDF]


Home page
Postgrad. Med. J.Home page
A-P Bai and Q Ouyang
Probiotics and inflammatory bowel diseases.
Postgrad. Med. J., June 1, 2006; 82(968): 376 - 382.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
J. I. Fenton and N. G. Hord
Stage matters: choosing relevant model systems to address hypotheses in diet and cancer chemoprevention research
Carcinogenesis, May 1, 2006; 27(5): 893 - 902.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
Y. Tao, K. A. Drabik, T. S. Waypa, M. W. Musch, J. C. Alverdy, O. Schneewind, E. B. Chang, and E. O. Petrof
Soluble factors from Lactobacillus GG activate MAPKs and induce cytoprotective heat shock proteins in intestinal epithelial cells
Am J Physiol Cell Physiol, April 1, 2006; 290(4): C1018 - C1030.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
P. A. Ruiz and D. Haller
Functional Diversity of Flavonoids in the Inhibition of the Proinflammatory NF-{kappa}B, IRF, and Akt Signaling Pathways in Murine Intestinal Epithelial Cells
J. Nutr., March 1, 2006; 136(3): 664 - 671.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
A. G. Buret
How Stress Induces Intestinal Hypersensitivity
Am. J. Pathol., January 1, 2006; 168(1): 3 - 5.
[Full Text] [PDF]


Home page
Infect. Immun.Home page
A. Sturm, K. Rilling, D. C. Baumgart, K. Gargas, T. Abou-Ghazale, B. Raupach, J. Eckert, Ralf. R. Schumann, C. Enders, U. Sonnenborn, et al.
Escherichia coli Nissle 1917 Distinctively Modulates T-Cell Cycling and Expansion via Toll-Like Receptor 2 Signaling
Infect. Immun., March 1, 2005; 73(3): 1452 - 1465.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
F. Shanahan
Physiological Basis for Novel Drug Therapies Used to Treat the Inflammatory Bowel Diseases I. Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease
Am J Physiol Gastrointest Liver Physiol, March 1, 2005; 288(3): G417 - G421.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. R. Frey, A. Golovin, and D. B. Polk
Epidermal Growth Factor-stimulated Intestinal Epithelial Cell Migration Requires Src Family Kinase-dependent p38 MAPK Signaling
J. Biol. Chem., October 22, 2004; 279(43): 4451